IRIS Accounts Production v24.1.9.2 09953150 director 1.2.23 31.1.24 31.1.24 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh099531502023-01-31099531502024-01-31099531502023-02-012024-01-31099531502022-01-31099531502022-02-012023-01-31099531502023-01-3109953150ns15:EnglandWales2023-02-012024-01-3109953150ns14:PoundSterling2023-02-012024-01-3109953150ns10:Director12023-02-012024-01-3109953150ns10:PrivateLimitedCompanyLtd2023-02-012024-01-3109953150ns10:SmallEntities2023-02-012024-01-3109953150ns10:AuditExemptWithAccountantsReport2023-02-012024-01-3109953150ns10:SmallCompaniesRegimeForDirectorsReport2023-02-012024-01-3109953150ns10:SmallCompaniesRegimeForAccounts2023-02-012024-01-3109953150ns10:FullAccounts2023-02-012024-01-3109953150ns10:OrdinaryShareClass12023-02-012024-01-3109953150ns10:RegisteredOffice2023-02-012024-01-3109953150ns5:CurrentFinancialInstruments2024-01-3109953150ns5:CurrentFinancialInstruments2023-01-3109953150ns5:ShareCapital2024-01-3109953150ns5:ShareCapital2023-01-3109953150ns5:LeaseholdImprovements2023-02-012024-01-3109953150ns5:PlantMachinery2023-02-012024-01-3109953150ns5:FurnitureFittings2023-02-012024-01-3109953150ns5:MotorVehicles2023-02-012024-01-3109953150ns5:ComputerEquipment2023-02-012024-01-3109953150ns5:LeaseholdImprovements2023-01-3109953150ns5:PlantMachinery2023-01-3109953150ns5:FurnitureFittings2023-01-3109953150ns5:LeaseholdImprovements2024-01-3109953150ns5:PlantMachinery2024-01-3109953150ns5:FurnitureFittings2024-01-3109953150ns5:LeaseholdImprovements2023-01-3109953150ns5:PlantMachinery2023-01-3109953150ns5:FurnitureFittings2023-01-3109953150ns5:MotorVehicles2023-01-3109953150ns5:ComputerEquipment2023-01-3109953150ns5:MotorVehicles2024-01-3109953150ns5:ComputerEquipment2024-01-3109953150ns5:MotorVehicles2023-01-3109953150ns5:ComputerEquipment2023-01-3109953150ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-01-3109953150ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-01-3109953150ns5:DeferredTaxation2023-01-3109953150ns5:DeferredTaxation2023-02-012024-01-3109953150ns5:DeferredTaxation2024-01-3109953150ns10:OrdinaryShareClass12024-01-31
REGISTERED NUMBER: 09953150 (England and Wales)














UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 JANUARY 2024

FOR

CLAIRE DAVIES PHARMA CONSULTING LIMITED

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4

Report of the Accountants 8

CLAIRE DAVIES PHARMA CONSULTING LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 JANUARY 2024







DIRECTOR: Mrs C Milligan





REGISTERED OFFICE: 45 Queen Street
Deal
Kent
CT14 6EY





REGISTERED NUMBER: 09953150 (England and Wales)





ACCOUNTANTS: Higson & Co (Deal) Ltd
45 Queen Street
Deal
Kent
CT14 6EY

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

BALANCE SHEET
31 JANUARY 2024

2024 2023
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 57,559 69,233

CURRENT ASSETS
Stocks 5 7,650 12,210
Debtors 6 974 4,428
Cash at bank 126,441 148,906
135,065 165,544
CREDITORS
Amounts falling due within one year 7 7,832 16,173
NET CURRENT ASSETS 127,233 149,371
TOTAL ASSETS LESS CURRENT
LIABILITIES

184,792

218,604

PROVISIONS FOR LIABILITIES 8 8,859 10,022
NET ASSETS 175,933 208,582

CAPITAL AND RESERVES
Called up share capital 9 100 100
Retained earnings 175,833 208,482
SHAREHOLDERS' FUNDS 175,933 208,582

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

BALANCE SHEET - continued
31 JANUARY 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the director and authorised for issue on 18 August 2024 and were signed by:





Mrs C Milligan - Director


CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2024

1. STATUTORY INFORMATION

Claire Davies Pharma Consulting Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The Financial Statements are presented in round pounds sterling £.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover represents invoiced sales of services excluding value added tax. Revenue is recognised once the service has been completed.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Improvements to property - 10% on cost
Plant and machinery - 15% on reducing balance
Fixtures and fittings - 15% on reducing balance
Motor vehicles - 15% on reducing balance
Computer equipment - 33% on cost

Tangible fixed assets are tested for impairment annually.
It is the Company's policy to capitalise items with an estimated useful life in excess of two years, and for amounts in excess of £300.

Stocks
Work in progress is valued at the lower of cost and net realisable value.

Cost is calculated using the first-in, first-out method and includes all purchase, transport, and handling costs in bringing stocks to their present location and condition.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
Pension Costs are represented by Company contributions to the director's personal pension scheme.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2023 - 1 ) .

4. TANGIBLE FIXED ASSETS
Improvements Fixtures
to Plant and and
property machinery fittings
£    £    £   
COST
At 1 February 2023 55,270 499 6,297
Additions - - -
At 31 January 2024 55,270 499 6,297
DEPRECIATION
At 1 February 2023 38,945 69 4,290
Charge for year 5,527 65 301
At 31 January 2024 44,472 134 4,591
NET BOOK VALUE
At 31 January 2024 10,798 365 1,706
At 31 January 2023 16,325 430 2,007

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2024

4. TANGIBLE FIXED ASSETS - continued

Motor Computer
vehicles equipment Totals
£    £    £   
COST
At 1 February 2023 56,090 1,476 119,632
Additions - 2,108 2,108
At 31 January 2024 56,090 3,584 121,740
DEPRECIATION
At 1 February 2023 5,647 1,445 50,396
Charge for year 7,567 325 13,785
At 31 January 2024 13,214 1,770 64,181
NET BOOK VALUE
At 31 January 2024 42,876 1,814 57,559
At 31 January 2023 50,443 31 69,236

5. STOCKS
2024 2023
£    £   
Work-in-progress 7,650 12,210

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade debtors - 4,428
Directors' current accounts 974 -
974 4,428

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 90 -
Tax 3,246 9,012
Social security and other taxes 162 319
VAT 3,544 5,631
Other creditors - 245
Directors' current accounts - 246
Accrued expenses 790 720
7,832 16,173

8. PROVISIONS FOR LIABILITIES
2024 2023
£    £   
Deferred tax 8,859 10,022

CLAIRE DAVIES PHARMA CONSULTING LIMITED (REGISTERED NUMBER: 09953150)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 JANUARY 2024

8. PROVISIONS FOR LIABILITIES - continued

Deferred
tax
£   
Balance at 1 February 2023 10,022
Provided during year (1,163 )
Balance at 31 January 2024 8,859

9. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
100 Ordinary 1.00 100 100

10. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

During the year the following Directors Loan Accounts subsisted;

Directors Loan Account
A member of key management personnel

During the year the Director advanced the Company £158 (2023: £754)

During the year the Company repaid the Director £9,192 (2023: £1,378)

As at the year end the Director owed the Company £974 (2023: Company owed Director £246)

The loan is interest free and repayable upon demand.

CLAIRE DAVIES PHARMA CONSULTING LIMITED

REPORT OF THE ACCOUNTANTS TO THE DIRECTOR OF
CLAIRE DAVIES PHARMA CONSULTING LIMITED

The following reproduces the text of the report prepared for the director in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Director are not required to be filed with the Registrar of Companies.

As described on the Balance Sheet you are responsible for the preparation of the financial statements for the year ended 31 January 2024 set out on pages one to ten and you consider that the company is exempt from an audit.

In accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us.






Higson & Co (Deal) Ltd
45 Queen Street
Deal
Kent
CT14 6EY


Date: .............................................